VG

Vikas Goyal

Managing Partner at Trekk Venture Partners

Cambridge, Massachusetts

Overview 

Vikas Goyal is the Managing Partner and Co-Founder at Trekk Venture Partners, a biotech company in Cambridge, Massachusetts, with a focus on building, partnering, and investing in better medicines. He has a strong background in venture capital, financial modeling, and entrepreneurship, and has made significant investments in companies like Pandion Therapeutics and Spero Therapeutics, contributing to their growth and success.

Work Experience 

  • Managing Partner and Co-Founder

    2022 - Current

    Trekk is a venture capital firm dedicated to investing in early stage biotech companies developing life-changing medicines.

Trekk Venture Partners is a venture capital company that develops life-changing medicines.

  • Merck Integration

    2021 - 2021

  • SVP Business Development

    2019 - 2021

  • Board Member

    2018 - 2019

  • Board Member

    2016 - 2021

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Raised $510,499,755.00 from Pfizer Venture Investments, Novo Holdings, Invus, Polaris Partners, ShangPharma, Schrödinger, Timothy A. Springer, SR One, Omega Funds and EcoR1 Capital.

  • Board Member

    2018 - 2019

Nimbus Therapeutics uses computational technology to create selective small molecule therapeutics.

Raised $637,000,000.00 from Biotechnology Value Fund, RA Capital Management, Gates Frontier Fund, SR One, Pfizer Venture Investments, Bain Capital Life Sciences, Atlas Venture, Google Ventures, SV Health Investors and Lightstone Ventures.

  • Board Member

    2015 - 2019

  • Board Member

    2013 - 2019

  • Principal

    2011 - 2019

    Biotech venture capital for novel drug discovery and development companies in Boston and globally.

SR One is the corporate venture capital arm of GlaxoSmithKline.

  • Board Member

    2014 - 2018

Spero Therapeutics develops therapeutics for treatment of gram-negative infections.

Raised $443,556,000.00 from GlaxoSmithKline, Pfizer, OUP (Osage University Partners) and Cowen Investment Management.

  • Manager, Corporate Strategy & Development

    2010 - 2011

Infinity Pharmaceuticals engages in the discovery and development of medicines for the treatment of cancer and related conditions.

Raised $538,040,191.00 from Biotechnology Value Fund and Purdue Pharma.

  • Intern

    2009 - 2010

SR One is the corporate venture capital arm of GlaxoSmithKline.

Articles About Vikas

Relevant Websites